Emerging Longevity Ventures

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Repair Biotechnologies, Inc. is a biotechnology company founded in 2018 and based in Syracuse, New York. The company focuses on developing innovative therapies aimed at reversing the progression of age-related conditions such as immunosenescence and atherosclerosis. Utilizing a cholesterol-degrading platform, Repair Biotechnologies creates treatments that address conditions driven by excess or modified cholesterol, including atherosclerosis and familial hypercholesterolemia. Their approach centers on gene therapy and recombinant protein strategies, designed to be safe and well-tolerated, allowing patients to target the underlying causes of diseases associated with cholesterol accumulation.